AMIX (Autonomix Medical) EBIT: $-16.72 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $5.77
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical EBIT?

Autonomix Medical AMIX -12.48% 15 EBIT is $-16.72 Mil as of Mar. 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

Autonomix Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.72 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Autonomix Medical's annualized ROC % for the quarter that ended in Mar. 2026 was -3,464.56%. Autonomix Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -54,687.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Autonomix Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 221.07%.

Autonomix Medical  (NAS:AMIX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Autonomix Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-10.948 * ( 1 - 0% )/( (0.02 + 0.612)/ 2 )
=-10.948/0.316
=-3,464.56 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10.211 - 1.65 - ( 9.934 - max(0, 1.65 - 10.191+9.934))
=0.02

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.6 - 1.112 - ( 7.004 - max(0, 1.705 - 7.581+7.004))
=0.612

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Autonomix Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-10.664/( ( (0.02 + max(-1.393, 0)) + (0.019 + max(-1.128, 0)) )/ 2 )
=-10.664/( ( 0.02 + 0.019 )/ 2 )
=-10.664/0.0195
=-54,687.18 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.257) - (1.65 + 0 + 0)
=-1.393

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.577) - (1.112 + 0 + 0.593)
=-1.128

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Autonomix Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-16.715/-7.561
=221.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical EBIT Related Terms

Autonomix Medical EBIT Historical Data

* Premium members only.

The historical data trend for Autonomix Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical EBIT Chart

Autonomix Medical Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBIT
-1.99 -15.35 -11.23 -16.72

Autonomix Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.15 -3.34 -7.45 -3.26 -2.67

AMIX vs BJDX, LUDG, ALURD: EBIT Comparison

For the Medical Devices subindustry, Autonomix Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autonomix Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Autonomix Medical's EV-to-EBIT falls into.


AMIX
15GF Score
Autonomix Medical Inc AMIX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autonomix Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-16.72 Mil mean?
Autonomix Medical (AMIX) has a EBIT of $-16.72 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Autonomix Medical.
Is Autonomix Medical's EBIT too high?
Autonomix Medical's current EBIT is $-16.72 Mil. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's EBIT compare to BJDX and LUDG?
Autonomix Medical's EBIT of $-16.72 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Autonomix Medical. Autonomix Medical's current EBIT is $-16.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current EBIT of $-16.72 Mil. The current EBIT is $-16.72 Mil. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current EBIT is $-16.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.77
Price